La cadena de opciones muestra datos clave de las opciones de acciones de Silexion Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Silexion Therapeutics..

Silexion Therapeutics (NASDAQ:SLXN) Bolsa, Cadena de Opciones

Silexion Therapeutics

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACLS

AMKR

BHAT

BNAI

FLNC

GNPX

HLIT

LIXT

LSCC

NLSP

OCEA

PRLD

SGRY

SLQT

SLXN

TANH

VSTE

Lattice Semiconductor sorprende con un alza del 14,7% en el premercado. Descubre qué otras acciones están en movimiento.

Acciones de Lattice Semiconductor (LSCC) suben un 15%; 20 acciones que se mueven en el premercado

APPS

AVGR

BBAI

COHR

DGLY

FORM

MBRX

MTRX

PTIX

RANI

RXRX

SBET

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SWKS

Coherent sorprende con sus resultados trimestrales y dispara sus acciones un 15,5%. ¿Qué otras empresas se mueven en el premercado de EE.UU.?

Acciones de Coherent (COHR) se disparan un 15%; 20 acciones que se mueven en el premercado de EE.UU.

ALTG

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CARM

CNCK

CRGX

FBNC

MGOL

NAOV

NATR

OFIX

RNGR

TSLA

VREX

XFOR

Meta sube en la preapertura tras superar expectativas. Descubre qué otras acciones están registrando fuertes movimientos hoy.

Acciones de Meta Platforms (META) están cotizando al alza; 20 acciones que se mueven en el premercado de EE.UU.

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics Corp

New graduates expect to have a starting, pre-tax income of $101,500, according to a report from <a href="https://www.ziprecruiter-research.org/annual-grad-report#04">ZipRecruiter</a>. Meanwhile, the average starting, pre-tax salary for first-year workers is $68,400.
However, that six-figure starting salary isn't totally out of the question, especially for those who majored in high-demand fields. ZipRecruiter identified 10 fields where it's possible for a new hire to earn big straight out of the gate.
Don't Miss:
<ul class="wp-block-list">
<li>GoSun's breakthrough rooftop EV charger already has 2,000+ units reserved —<a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor"> become an investor in this $41.3M clean energy brand today</a>.</li>
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market.<a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment"> Back a bold new approach to cancer treatment with high-growth potential.</a></li>
</ul>
According to data from ZipRecruiter's website, these fields include:
<ol class="wp-block-list">
<li>Consulting: <a href="https://www.ziprecruiter.com/Salaries/Consultant-Salary#Yearly">$21,000 to $247,000</a></li>
<li>Program Management: <a href="https://www.ziprecruiter.com/Salaries/Program-Manager-Salary">$38,500 to $157,000</a></li>
<li>Nursing: <a href="https://www.ziprecruiter.com/Salaries/Registered-Nurse-Salary#Yearly">$15,500 to $150,000</a> </li>
<li>Industrial Maintenance: <a href="https://www.ziprecruiter.com/Salaries/Industrial-Maintenance-Salary#:~:text=Industrial%20Maintenance%20Salary&amp;text=%2470%2C000%20is%20the%2025th%20percentile,Salaries%20below%20this%20are%20outliers.&amp;text=%24103%2C500%20is%20the%2075th%20percentile.">$38,500 to $134,500 </a></li>
<li>Telecommunications: <a href="https://www.ziprecruiter.com/Salaries/Telecommunications-Specialist-Salary">$36,500 to $115,500</a> </li>
<li>Business Development: <a href="https://www.ziprecruiter.com/Salaries/Business-Development-Salary">$36,500 to $149,000</a> </li>
<li>Data Specialist: <a href="https://www.ziprecruiter.com/Salaries/Data-Management-Specialist-Salary">$28,500 to $132,000</a></li>
<li>Home Health Care: <a href="https://www.ziprecruiter.com/Salaries/Home-Health-Physical-Therapist-Assistant-Salary#Yearly">$31,500 to $155,500</a> </li>
<li>Real Estate: <a href="https://www.ziprecruiter.com/Salaries/Real-Estate-Agent-Salary">$28,500 to $149,500</a></li>
<li>Procurement: <a href="https://www.ziprecruiter.com/Salaries/Procurement-Specialist-Salary#Yearly">$32,500 to $111,500</a></li>
</ol>
ZipRecruiter Career Expert Sam DeMase told <a href="https://www.cnbc.com/2025/04/23/career-fields-where-new-grads-can-command-a-100000-starting-salary.html">CNBC</a> some of these fields one would expect to find on the list, while others are more surprising.&nbsp;
"Program management is a very overlooked six-figure entry-level field," DeMase said. "I think that recent and rising grads should be looking at program management. If you're someone who is organized, has leadership potential, can multitask really well, can communicate exceptionally well — those skill sets are really valued in program management."&nbsp;
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, with minimum investments as low as $100</a>.
Meanwhile, he called nursing a "classic in-demand and high-paying" field and noted that consulting salaries, even for entry-level employees, are known to be comparatively high.
However, DeMase he told CNBC that starting salaries can range quite dramatically depending on location. Bigger cities like New York City and Los Angeles are likely to pay better, while those starting out in smaller locales like Kansas City, Missouri may find themselves on the lower-end of the pay scale.
As for the overall pay expectations of 2025 grads, DeMase said that the disconnect between salary expectations and reality may be attributed to a number of factors.&nbsp;
"Social media definitely alters the perception of reality for a lot of these rising and recent grads," he said. "It puts a lot of wealth on display and can skew that perception by showcasing the exceptions and not the rules." Additionally, high costs of living and general inexperience with the job market are likely leading to higher expectations.&nbsp;
Recents grads are thinking "if my cost of living is going up, my salary should be going up, too," DeMase says. Meanwhile, <a href="https://www.reuters.com/business/world-at-work/us-real-earnings-stalled-across-age-income-groups-past-year-study-shows-2025-05-22/">studies show</a> that wages have stagnated, and have been outpaced by inflation since at least 2019.&nbsp;
See Next:
<ul class="wp-block-list">
<li>$100k in assets? Maximize your retirement and cut down on taxes:<a href="https://www.benzinga.com/money/wideradvisor-retirement-planning"> Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>

Personal Finance

Think You'll Make $100K Right Out Of College? In These 10 Fields, You Might Be Right

Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) has outperformed the market over the past 5 years by 47.31% on an annualized basis producing an average annual return of 62.0%. Currently, Howmet Aerospace has a market capitalization of $71.39 billion. 
Buying $1000 In HWM: If an investor had bought $1000 of HWM stock 5 years ago, it would be worth $10,903.21 today based on a price of $176.85 for HWM at the time of writing.
<h3>Howmet Aerospace's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750970711_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Howmet Aerospace 5 Years Ago Would Be Worth Today

Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) reported fourth-quarter financial results for fiscal 2025 Thursday after the market close. Here&#8217;s a rundown of the athletic footwear and <a href="https://www.benzinga.com/pressreleases/25/06/b46127659/nike-inc-reports-fiscal-2025-fourth-quarter-and-full-year-results">apparel company&#8217;s report</a>.
Q4 Earnings: Nike reported fourth-quarter revenue of $11.1 billion, beating analyst&nbsp;<a href="http://benzinga.com/quote/nke/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $10.72 billion. The company&nbsp;reported fourth-quarter earnings of 14 cents per share, beating analyst estimates of 11 cents per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Total revenue was down 12% year-over-year in the quarter. Nike Direct revenues were $4.4 billion in the quarter, down 14% year-over-year. Nike Brand revenues totaled $10.8 billion, down 11%, and Wholesale revenues fell 9% to $6.4 billion.
Here's a breakdown of sales by region:
<ul class="wp-block-list">
<li>North America:&nbsp;down 11%</li>
<li>Greater China:&nbsp;down 21%</li>
<li>Europe, Middle East &amp; Africa:&nbsp;down 9%</li>
<li>Asia Pacific and Latin America:&nbsp;down 8%</li>
</ul>
Inventories were $7.5 billion at the end of the fourth quarter, flat compared to the prior year. Nike ended the period with $9.2 billion in cash, cash equivalents and short-term investments.
&#8220;While our financial results are in-line with our expectations, they are not where we want them to be. Moving forward, we expect our business to improve as a result of the progress we&#8217;re making through our Win Now actions,&#8221; said&nbsp;Elliott Hill, president and CEO of Nike.
&#8220;As we enter a new fiscal year, we are turning the page and the next step is aligning our teams to lead with sport through what we are calling the sport offense. This will accelerate our Win Now actions to reposition our business for future growth.&#8221;
Nike said it returned $591 million to shareholders in the form of dividends and repurchased $202 million of its common stock in the quarter. 
Nike CFO Matthew Friend said the company expects headwinds to moderate moving forward. 
Nike is expected to provide forward guidance on its earnings call with investors and analysts, which is scheduled to start at 5 p.m. ET.
NKE Price Action: <a href="http://benzinga.com/quote/nke" target="_blank" rel="noreferrer noopener">Nike shares</a> were bouncing around following the report, last down 1.07% in after-hours at $61.87 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/46124290/sp-500-hits-record-highs-and-history-says-the-best-is-yet-to-come">S&amp;P 500 Trades At Record Highs—And History Says The Best Is Yet To Come</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46113250/how-to-earn-500-a-month-from-nike-stock-ahead-of-q4-earnings-2">How To Earn $500 A Month From Nike Stock</a></li>
</ul>
Photo: Roman Zaiets/Shutterstock.com

Earnings

Sports

Global

Nike Q4 Earnings: Revenue Beat, EPS Beat, Headwinds Expected To Moderate Moving Forward, Company Playing 'Sport Offense'

Entry into a Material Definitive Agreement.
&nbsp;
Equity Purchase Agreement
On June 22, 2025, Zhibao Technology Inc., a Cayman Islands exempted company (the "Company"), entered into an Equity Purchase Agreement with Hudson Global Ventures, LLC, a Nevada limited liability company ("Hudson" and the agreement, the "Hudson EPA") in connection with setting up certain equity line of credit facility (the "Hudson ELOC"). Pursuant to the Hudson EPA, Hudson has agreed to purchase up to $15,000,000 (the "Aggregate Limit") of the Company's Class A ordinary shares, par value $0.0001 per share (the "Class A Ordinary Shares") over a two-year period commencing on June 22, 2025, subject to earlier terminations (the "Commitment Period"). Under the Hudson EPA, the Company may, by delivering a written notice to Hudson (each such notice, a "Put Notice") setting forth the shares (such shares, the "Put Shares", and the date on which such Put Notice is delivered, the "Put Date"), directing Hudson to purchase the Class A Ordinary Shares in an amount (i) not lower than $25,000 (calculated using the "Initial Purchase Price", which is equal to 90% of closing price of the Class A Ordinary Shares on Nasdaq on the trading day immediately preceding the respective Put Date)) and (ii) up to the lesser of (a) $2,000,000.00, or (b) 200% of the average daily trading value (calculated as the average trading volume of the Class A Ordinary Shares on Nasdaq during the three (3) trading days immediately preceding the respective Put Date multiplied by the lowest closing price of the Class A Ordinary Shares during the three (3) trading days immediately preceding the respective Put Date. Hudson is not obligated to purchase any Class A Ordinary Shares which would result in Hudson beneficially owning, directly or indirectly, at the time of the proposed issuance, more than 4.99% of the Class A Ordinary Shares issued and outstanding. Hudson will pay a purchase price per share equal to the lesser of (i) the Initial Purchase Price or (ii) the "Market Price," which is equal to 90% of the average closing price of the Class A Ordinary Shares on Nasdaq during period commencing on the Put Date and continuing through the date that is three (3) trading days immediately following the date when Hudson receives the Put Shares in its brokerage account (such date, the "Clearing Date") associated with the applicable Put Notice (the "Valuation Period").
Additionally, the Company is obligated to issue to Hudson an aggregate amount of Class A Ordinary Shares equal to (i) 140,000 Class A Ordinary Shares (the "Initial Commitment Shares"), plus (ii) any "Make-Whole Commitment Shares" (together with the Initial Commitment Shares, the "Commitment Shares") calculated by dividing 140,000 by the closing price of Class A Ordinary Shares on the date that is the earlier of (i) December 21, 2025 (being the six (6) calendar months after the date of Hudson EPA) or (ii) the first date that the initial resale registration statement registering the Initial Committee Shares, Make-Up Commitment Shares and shares underlying the Aggregate Limit (the "Resale Registration Statement") is declared effective by the SEC (the "Measurement Date"), if the closing price of Class A Ordinary Shares on the Measurement Date is less than the closing price of the Class A Ordinary Shares on the date of the Hudson EPA.
The Hudson EPA contains customary representations, warranties, agreements and conditions to completing future sale transactions, indemnification rights and obligations of the parties.
&nbsp;
Registration Rights Agreement
On June 22, 2025, the Company also entered into a Registration Rights Agreement with Hudson (the "Hudson RRA"). Pursuant to the Hudson RRA, the Company is required to, as soon as practicable but no later than One Hundred and Eighty (180) calendar days following June 22, 2025 (the "Filing Deadline"), file with the U.S. Securities and Exchange Commission the Resale Registration Statement registering the resale of the Class A Ordinary Shares that Hudson is entitled to receive pursuant to the Hudson EPA, including any Class A Ordinary Shares issued or issuable upon any share split, dividend or other distribution, recapitalization or similar event with respect to the foregoing, and to use its commercially reasonable efforts to have such registration statement declared effective within two hundred ten (210) calendar days from June 22, 2025 and as soon as practicable after the filing thereof.

Offerings

Contracts

ZBAO

On June 22, 2025 Zhibao Technology Enters $15M Equity Purchase Agreement With Hudson Global Ventures

<a href="https://www.youtube.com/watch?v=eIpB6BepvNM">https://www.youtube.com/watch?v=eIpB6BepvNM</a>

General

President Trump Says Texas Instruments Going To Spend $60B In U.S.

Concentrix Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) released its second-quarter results after Thursday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/06/g46127570/concentrix-reports-second-quarter-2025-results">details in the report. </a>
The Details: Concentrix reported quarterly earnings of $2.70 per share, which missed the analyst consensus estimate of $2.75. Quarterly revenue came in at $2.42 billion, which beat the Street estimate of $2.38 billion.
Read Next: <a href="https://www.benzinga.com/news/space/25/06/46055895/ast-spacemobile-stock-downgraded-rocket-lab-prepares-electron-launch-space-stock-countdown?utm_source=articleShare">AST SpaceMobile Stock Downgraded, Rocket Lab Prepares Electron Launch: Space Stock Countdown</a>
&#8220;In the second quarter, we continued to outperform expectations on revenue growth despite some mid-quarter volatility,&#8221; said Chris Caldwell, CEO of Concentrix. 
&#8220;As we look ahead to the second half, we are seeing an accelerated pace of activity with both existing and new clients, and improving margins. Further, our AI investments are on pace to be accretive to the business by year-end as planned,&#8221; Caldwell added.
Outlook: Concentrix narrowed its fiscal 2025 adjusted EPS guidance from FY2025 Adj. between $11.18 and $11.77 to between $11.53 and $11.76, versus the $11.54 analyst estimate.
The company raised its fiscal 2025 revenue outlook from between&nbsp;$9.49 billion and $9.63 billion&nbsp;to between $9.72 billion and $9.81 billion, versus the&nbsp;$9.61 billion&nbsp;estimate.
CNXC Price Action: According to data from<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw"> Benzinga Pro</a>, Concentrix stock was down 8.49% at $50.45 in Thursday's extended trading. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46056665/unitedhealth-cvs-among-major-insurers-to-fast-track-prior-authorizations-will-it-cut-profits-even-more?utm_source=articleShare">UnitedHealth, CVS Among Major Insurers To Fast-Track Prior Authorizations: Will It Cut Profits Even More?</a></li>
</ul>
Image: Shutterstock&nbsp;

After-Hours Center

Tech

CNXC

Concentrix Stock Slips After Mixed Q2 Results: Details

Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) reported quarterly losses of $(3.70) per share which missed the analyst consensus estimate of $(1.07) by 244.83 percent. This is a 306.59 percent decrease over losses of $(0.91) per share from the same period last year.

Earnings Misses

AEMD

Aethlon Medical Q4 EPS $(3.70) Misses $(1.07) Estimate

INDA

President Trump Says Just Signed Deal With China Wednesday; Have One Coming Up With India; Did Not Say What Sort Of Deal With China Was Signed

TOP Ships Inc. (the "Company" or "TOP Ships") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOPS#NYSE">TOPS</a>), an international owner and operator of modern, fuel-efficient "ECO" tanker vessels, announced today that the application of Rubico Inc. ("Rubico"), to list its common shares on the Nasdaq Capital Market has been approved. In addition, the registration statement on Form 20-F filed by Rubico in connection with its spin-off from Top Ships Inc has been declared effective by the U.S. Securities and Exchange Commission (the "SEC").
The distribution of Rubico common shares to securityholders of TOP Ships is expected to be made within July 2025. TOP Ships will announce the distribution date via a future press release.
Rubico common shares are expected to commence trading on a standalone basis on the Nasdaq Capital Market on the first trading day after the date of distribution, under the ticker "RUBI".

Dividends

TOPS

TOP Ships Spin-Off Rubico Approved For Nasdaq Listing; Share Distribution Expected In July Under Ticker "RUBI"

Biotech

PRQR

ProQR Submits Clinical Trial Application To EMA To Initiate Phase 1 Trial Of AX-0810 Targeting NTCP

Enerpac Tool Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAC#NYSE">EPAC</a>) affirms FY2025 sales outlook from $610.000 million-$625.000 million to $610.000 million-$625.000 million vs $612.300 million estimate.

Guidance

EPAC

Enerpac Tool Group Affirms FY2025 Sales Guidance of $610.000M-$625.000M vs $612.300M Est

FORT WORTH, Texas, June 26, 2025 /PRNewswire/ -- AZZ Inc.&nbsp;(NYSE:<a href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>), the leading independent provider of hot-dip galvanizing and coil coating solutions, today announced its Board of Directors has authorized a first quarter cash dividend in the amount of $0.20 per share on the Company's outstanding shares of common stock.&nbsp;The dividend is payable on July 31, 2025, to shareholders of record as of the close of business on July 10, 2025.

AZZ Raises Quarterly Cash Dividend By 17.6% From $0.17 To $0.20 Per Share

Full-scale platform transitions to forward flight, accelerates mission system integration, and pushes the boundaries of maritime VTOL autonomy

AVAV

AeroVironment's Wildcat Reaches Development Milestones In DARPA's ANCILLARY Program's EVADE Demonstration

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed up 127.05% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 51.16% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 12.32% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed up 11.74% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 11.67% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 10.87% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed up 9.69% at $4.26</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 9.47% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed up 9.14% at $1.12</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 8.85% at $8.32</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 4.75% at $0.41</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed down 99.80% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 13.04% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed down 12.26% at $0.20</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 9.25% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 8.82% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 7.36% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 6.76% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed down 6.12% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 5.50% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 4.88% at $0.30</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed down 3.81% at $0.45</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 3.33% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 3.11% at $8.02</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

BLGVF

BLOZF

BMMJ

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNTMF

CRBP

CXXIF

FUAPF

GBHPF

GNLN

ITHUF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

MGWFF

OILFF

RMHB

RSSFF

TGIFF

TLRY

UGRO

XXII

Cannabis Stock Gainers And Losers From June 26, 2025

Enerpac Tool Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAC#NYSE">EPAC</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.47 by 8.51 percent. This is a 8.51 percent increase over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $159.000 million which beat the analyst consensus estimate of $156.500 million by 1.60 percent. This is a 5.73 percent increase over sales of $150.389 million the same period last year.

Earnings Beats

Enerpac Tool Group Q3 Adj. EPS $0.51 Beats $0.47 Estimate, Sales $159.000M Beat $156.500M Estimate

F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) has outperformed the market over the past 20 years by 4.84% on an annualized basis producing an average annual return of 13.31%. Currently, F5 has a market capitalization of $16.74 billion. 
Buying $1000 In FFIV: If an investor had bought $1000 of FFIV stock 20 years ago, it would be worth $12,169.65 today based on a price of $289.09 for FFIV at the time of writing.
<h3>F5's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750969818_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FFIV

Here's How Much $1000 Invested In F5 20 Years Ago Would Be Worth Today

WIIM

AOUT

American Outdoor Brands shares are trading higher after the company reported better-than-expected Q4 financial results.

Management

CORRECTION: Hillenbrand Appointed Megan Walke, To Serve As The Interim CFO, Effective June 28, 2025

Concentrix shares are trading lower after the company reported a Q2 adjusted EPS miss and narrowed its FY25 adjusted EPS guidance.

BBLG

Bone Biologics Regains Nasdaq Compliance With Minimum Bid Rule

Health Care

Press Releases

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Silexion Therapeutics Collaborates with Multi Billion Dollar Clinical Development Player, Advancing Revolutionary Cancer Treatment Toward Clinical Trials

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

AIM ImmunoTech

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

CEL-SCI

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Genprex

IN8bio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mainz Biomed

PharmaCyte Biotech

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Comments

Silexion Therapeutics

Silexion Therapeutics (SLXN) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL